Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash from Operations (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Cash from Operations for 6 consecutive years, with 32002000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 16.74% to 32002000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 135319000.0, a 22.1% decrease, with the full-year FY2025 number at 135319000.0, down 22.1% from a year prior.
  • Cash from Operations was 32002000.0 for Q4 2025 at TScan Therapeutics, up from 32464000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 8017000.0 in Q3 2023 to a low of 37586000.0 in Q1 2025.
  • A 5-year average of 21133950.0 and a median of 22804500.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 147.15% in 2023, then plummeted 448.24% in 2024.
  • TScan Therapeutics' Cash from Operations stood at 14380000.0 in 2021, then dropped by 11.34% to 16010000.0 in 2022, then crashed by 48.44% to 23766000.0 in 2023, then decreased by 15.34% to 27412000.0 in 2024, then decreased by 16.74% to 32002000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Cash from Operations are 32002000.0 (Q4 2025), 32464000.0 (Q3 2025), and 33267000.0 (Q2 2025).